

API's R&D PORTFOLIO

PRODUCT NAME	THERAPEUTIC CLASS	CAS nr.
ABACAVIR SULFATE	Antiviral (HIV)	188062-50-2
ABIRATERONE ACETATE	Antineoplastic	154229-18-2
ACLIDINIUM BROMIDE	Bronchodilator (COPD)	320345-99-1
ALDOXORUBICIN HYDROCHLORIDE	Antineoplastic	1361563-03-2
ALITRETINOIN	Antineoplastic; Antipsoriatic	5300-03-8
ALOGLIPTIN BENZOATE	Antidiabetic	850649-62-2
ATAZANAVIR SULFATE	Antiviral (HIV)	229975-97-7
AZACITIDINE	Antineoplastic	320-67-2
BEXAROTENE	Antineoplastic	153559-49-0
BLONANSERIN	Antipsychotic	132810-10-7
BOSENTAN MONOHYDRATE	Antihypertensive	157212-55-0
CANGRELOR TETRASODIUM	Antithrombotic	163706-36-3
CERITINIB	Antineoplastic	1032900-25-6
CLOFARABINE	Antineoplastic	123318-82-1
COBIMETINIB HEMIFUMARATE	Antineoplastic	934660-93-2
DANTROLENE SODIUM	Antispasmodic	14663-23-1
DAPTOMYCIN (standard and sterile)	Antibacterial	103060-53-3
DECITABINE	Antineoplastic	2353-33-5
DIHYDROERGOTAMINE MESYLATE	Antimigraine	6190-39-2
EFINACONAZOLE	Antimicrobial	164650-44-6
ENZALUTAMIDE	Antineoplastic	915087-33-1
ERGOTAMINE	Antimigraine	113-15-5
FENRETINIDE	Antineoplastic	65646-68-6
FIDAXOMICIN	Antibiotic	873857-62-6
INDACATEROL MALEATE	Bronchodilator	753498-25-8
IVABRADINE HYDROCHLORIDE	Antianginal	148849-67-6
LENVATINIB MESYLATE	Antineoplastic	857890-39-2
LURASIDONE HYDROCHLORIDE	Antipsychotic	367514-88-3
NINTEDANIB ESYLATE	Antineoplastic	656247-17-5
OLAPARIB	Antineoplastic	763113-22-0
OSPEMIFENE	Postmenopausal treatment	128607-22-7
PITAVASTATIN CALCIUM	Antilipemic	147526-32-7
POMALIDOMIDE	Antineoplastic	19171-19-8
PREGABALIN	Antiepileptic	148553-50-8
PRISTINAMYCIN	Antibacterial	8065-94-9
RALOXIFENE HYDROCHLORIDE	Antiosteoporotic	82640-04-8
RITONAVIR (Form I and II)	Antiviral (HIV)	155213-67-5

DISCLAIMER: These APIs are supplied solely: for performing the strictly necessary studies and trials aimed to the obtainment of an AIC or of a marketing authorization, according to Article 10 of directive 2001/83/CE, or for experimental purposes aimed to scientific innovation, or under an agreement or a contract for a co-development aimed to obtain a marketing authorization (dossiers). Any other use that may constitute a violation of any possible related exclusivity rights of the owner(s) of relevant European patents and/or relevant related national patents and/or supplementary protection certificates (SPC), is not allowed. In case of breach of this clause, you will keep us fully indemnified and harmless from any claims and consequences arising out of such use and breach.

PRODUCT NAME	THERAPEUTIC CLASS	CAS nr.
ROTIGOTINE	Anti-Parkinson	99755-59-6
RUCAPARIB	Antineoplastic	283173-50-2
TAVABOROLE	Antimicotic	174671-46-6
TAZAROTENE	Antipsoriatic; Antiacne	118292-40-3
TEICOPLANIN	Antibacterial	61036-64-4
TERIFLUNOMIDE	Agents for Multiple Sclerosis	108605-62-5
THIOTEPA	Antineoplastic	52-24-4
TIOTROPIUM BROMIDE	Bronchodilator (COPD)	136310-93-5
TOFACITINIB CITRATE	Antiarthritic	540737-29-9
TOLVAPTAN	Diuretic	150683-30-0
UMECLIDINIUM BROMIDE	Bronchodilator (COPD)	869113-09-7
VALGANCICLOVIR HYDROCHLORIDE (amorphous and crystalline)	Antiviral	175865-59-5
VILANTEROL TRIFENATATE	Bronchodilator (COPD)	503070-58-4
VILAZODONE HYDROCHLORIDE	Antidepressant	163521-08-2
VILDAGLIPTIN	Antidiabetic	274901-16-5

DISCLAIMER: These APIs are supplied solely: for performing the strictly necessary studies and trials aimed to the obtainment of an AIC or of a marketing authorization, according to Article 10 of directive 2001/83/CE, or for experimental purposes aimed to scientific innovation, or under an agreement or a contract for a co-development aimed to obtain a marketing authorization (dossiers). Any other use that may constitute a violation of any possible related exclusivity rights of the owner(s) of relevant European patents and/or relevant related national patents and/or supplementary protection certificates (SPC), is not allowed. In case of breach of this clause, you will keep us fully indemnified and harmless from any claims and consequences arising out of such use and breach.

PAGE 2 of 2



Olon S.p.A.

Strada Rivoltana km. 6/7 20090 Rodano (Milan) - ITALY
 Phone : +39 02.9523.1 - Fax +39 02.9523.5111 e-mail: info@olonspa.it www.olonspa.com